Does Ozempic Affect Your Sex Drive? What the Research Shows

It is one of the most-searched questions about these medicines and one of the least-covered: does a GLP-1 change your sex drive? The honest answer is that it goes both ways, and which way appears to depend on who you are and on what the weight loss is doing to the rest of your body.

Do GLP-1s increase or decrease sex drive?

Both, in roughly equal measure. In a 2025 Kinsey Institute survey of 2,000 single U.S. adults, 155 of whom had used a GLP-1, 18% said their sexual desire increased and 16% said it decreased. On sexual function specifically, 16% said it improved and 12% said it worsened. About half (52%) said the medication had affected their sex life in some way.

That is self-reported survey data, not a clinical trial — but it captures something the clinical literature also shows: the effect is real, common enough to matter, and not uniform in direction.

Why sex drive often improves on a GLP-1

For many men, the mechanism is testosterone. Obesity suppresses testosterone, and losing weight raises it. In a study presented at ENDO 2025, 234 men taking semaglutide, dulaglutide, or tirzepatide lost weight — 117 kg to 108 kg on average — and saw total testosterone rise from 312 to 368 ng/dL. The share of men with testosterone in the normal range climbed from 54% to 76%.

Beyond hormones, a 2025 review in Biomolecules describes several ways GLP-1s could improve erectile function: better blood-vessel and nitric-oxide function, lower inflammation, and the cardiovascular benefit of the weight loss itself. Erectile difficulty is often an early sign of vascular disease, so improving the vasculature plausibly improves the symptom. Some studies have also reported improved sperm measures.

Then there is the part no lab measures: feeling better in your own body. In the Kinsey survey, 16% said they were more comfortable with how they look naked — though 14% said they were less comfortable, which is its own honest finding.

Why sex drive sometimes drops instead

The evidence on the other side is real and should not be waved away. The same Biomolecules review flags a retrospective cohort of men with obesity but without diabetes, taking semaglutide for weight loss, in which newly diagnosed erectile dysfunction or a new prescription for an ED medication occurred in 1.47% versus 0.32% of comparators — a relative risk of roughly 4.5. That is a large relative difference on a small absolute base, from an observational study.

The proposed mechanism is the same one that makes these drugs work. GLP-1s act on the brain's reward and motivation circuitry, turning down the drive to seek food. Sexual desire runs through overlapping dopamine pathways, so it is biologically plausible that turning down one appetite turns down another. A 2025 case report in Sexual Medicine describes a 71-year-old woman who developed anorgasmia within two weeks of starting liraglutide, with normal sensation returning about two weeks after she switched to tirzepatide — a single case, not a frequency estimate, but a documented one.

What does the FDA adverse-event database show?

This is where coverage often goes wrong. An analysis of FDA adverse-event reports found 182 reports from men of erectile dysfunction, reduced libido, or orgasmic dysfunction on GLP-1s. But the disproportionality measure — the statistic that indicates whether a drug is linked to an event more often than other drugs are — came out at 0.41 (95% CI 0.36–0.48).

A value **below 1 means these events were reported *less* often for GLP-1s than for medicines in general**. The database therefore does not show a disproportionate safety signal, and any headline citing those 182 reports as proof of risk is misreading the statistic. Adverse-event databases also cannot establish cause, because they capture only what someone chose to report.

Why does the evidence point both ways?

Because the studies are looking at different people, and two effects run at the same time:

• Who is being studied. Men with obesity, type 2 diabetes, or low testosterone have the most to gain, and they are the group that tends to improve. The erectile-dysfunction signal appeared in men *without* diabetes taking semaglutide purely for weight loss.
• Metabolic gain versus reward damping. Weight loss improves hormones and blood flow, which helps. Reward-pathway damping may reduce desire. Which one wins likely differs person to person.
• How fast the weight is coming off. Very rapid loss brings low energy and nutritional gaps, and both blunt libido regardless of the drug.
• Everything else in the picture. Sleep, mood, relationship context, and body image all shift at the same time, and none of them are the medication.

Can GLP-1s make birth control stop working?

This is the most actionable thing on this page, and it is a labeled instruction rather than a theory. The Zepbound (tirzepatide) prescribing information tells patients using oral hormonal contraceptives to switch to a non-oral method, or add a barrier method, for 4 weeks after starting the medicine and for 4 weeks after each dose increase. Delayed stomach emptying can reduce how much of the pill is absorbed. This guidance is specific to tirzepatide; it does not appear in the semaglutide injection label.

Separately, the «Ozempic babies» phenomenon is not mysterious. Weight loss and improved insulin sensitivity can restore ovulation in people whose cycles had stopped, particularly with PCOS — so fertility can return sooner than expected. GLP-1s are not recommended in pregnancy, and the tirzepatide label directs patients to stop the medicine when a pregnancy is recognized.

What should you do if your sex drive changes?

• Say it out loud to your clinician. It is a medical symptom, not an awkward aside — and it is one of the few side effects people quietly stop their medication over.
• Ask whether testosterone is worth checking if you are a man with symptoms such as low energy, low desire, and poor morning erections. Obesity-related low testosterone is common and treatable.
• Look at how fast you are losing weight, and at your protein and calorie intake. Very rapid loss and undereating blunt libido on their own.
• Rule out the usual suspects. Thyroid problems, depression, sleep apnea, alcohol, and several common medications — including some antidepressants and blood-pressure drugs — affect sexual function far more often than a GLP-1 will.
• Sort out contraception before you need it, especially on tirzepatide and around every dose increase.

Do not stop a prescribed medicine on your own to test the theory. Dose size, dose timing, and switching to a different agent are all adjustments a clinician can make with you — and in the published case report, switching agents is exactly what resolved the symptom.